Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail could simplify treatment for dangerous lung lining infection

NCT ID NCT07432373

Disease control Sponsor: National University of Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests two different drug combinations for pleural infection, a serious infection of the lung lining that often requires surgery. The standard treatment uses two drugs (alteplase and DNase) given through a chest tube. This trial compares that to a new combination using alteplase and Tyloxapol. The goal is to see if the new combo works as well or better at clearing the infection and reducing the need for surgery. The study will involve 80 adults with pleural infection who have poor drainage from a chest tube.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alteplase (t-PA) combined with either DNase or Tyloxapol, given directly into the chest cavity
What this could lead to
If successful, this could offer a simpler, shorter treatment option for pleural infection, potentially reducing the need for surgery and hospital stays.
What could go wrong
This is a small, early-stage trial (80 people) that hasn't started yet. The new drug combo may not work as well as the standard, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with pleural infection (complex pleural effusion or empyema) with poor outflow (≤ 150 cc) from chest drain after 24 Hours of insertion in medical and non-medical wards from June 2023 to June 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria 1. Adult patient aged ≥ 18 years old 2. Patients with pleural infection (complex parapneumonic effusion or empyema) with poor pleural fluid drainage of ≤ 150 ml after 24 hours of chest drain insertion received either t-PA-DNAse or t-PA/Tyloxapol. 3. Clinical features consistent with pleural infection; fulfilling ≥ 2 of the following characteristics: i) Clinical evidence of infection, such as fever and or elevated C-reactive protein (CRP) or total white blood count (TWBC) ii) Complex pleural effusion proven by thoracic ultrasound is defined as the presence of fibrin strands or septations within the pleural cavity iii) Pleural fluid that fulfils at least one of the characteristics: * Frank Pus, * Exudative type of pleural effusion (according to light's criteria) * Gram stain or culture positive * Lactate dehydrogenase (LDH) \> 900U/L * Acidic with pH \< 7.2 * Glucose level \< 3.3 mmol/L Exclusion Criteria: 1. Incomplete data. 2. Medical records that cannot be retrieved.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Empyema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

empyema pleural empyema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National University of Malaysia, Faculty of Medicine

    RECRUITING

    Cheras, Kuala Lumpur, 56000, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.